HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
2,2',3,3',4,5',6'-Heptachlorobiphenyl
PCB 177 · PCB NO 177 · PCB No. 177 10 μg/mL in Isooctane · 2,2',3,3',4',5,6-Heptachlorobiphenyl · L20017700IO PCB No. 177 10μg/mLin Isooctane · 2,2',3,3',4,5',6'-Heptachloro-1,1'-biphenyl · 1,1'-Biphenyl, 2,2',3,3',4,5',6'-heptachloro- · 2,2',3,3',4',5,6-HEPTACB UNLABELED CERTIFIED STANDARD
Identifikatoren & physikalische Daten
| CAS No. | 52663-70-4 |
|---|---|
| Summenformel | C12H3Cl7 |
| Durchschnittliche Molmasse | 395,3 g/mol |
| Monoisotopische Masse | 391,805444 g/mol |
| SMILES | Clc1ccc(-c2c(Cl)c(Cl)cc(Cl)c2Cl)c(Cl)c1Cl |
| InChIKey | CXOYNJAHPUASHN-UHFFFAOYSA-N |
| PubChem CID | 40477 |
| EC No. | 690-203-6 |
| DTXSID | DTXSID2074164 |
Chemische & physikalische Eigenschaften
| XLogP | 7,4 |
|---|---|
| Polarare Oberfläche (TPSA) | 0 |
| H-Brücken-Donoren | 0 |
| H-Brücken-Akzeptoren | 0 |
| Frei drehbare Bindungen | 1 |
| Schwere Atome | 19 |
| Formalladung | 0 |
| Komplexität | 298 |
| LogP (Verteilungskoeffizient) | 6.73 |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| Collision Cross Section | 170.7 Ų [M]+ [CCS Type: TIMS, Method: calibration with PAHs] |
| Schmelzpunkt | 131.31°C (estimate) |
| Siedepunkt | 479.43°C (rough estimate) |
| Dichte | 1.6580 (rough estimate) |
| Brechungsindex | 1.6330 (rough estimate) |
| Löslichkeit | 4.82ug/L(20 ºC) |
| Henry-Konstante | 2.1×10-2 mol/(m3Pa) at 25℃, Bamford et al. (2002) |
| EPA chemische Informationen | 2,2',3,3',4,5',6'-Heptachlorobiphenyl (52663-70-4) |
Sicherheit & Vorschriften
| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 100% (3 of 3) of all reports.Not ClassifiedAggregated GHS information provided per 3 reports by companies from 1 notifications to the ECHA C&L Inventory. |
|---|---|
| Regulatorische Informationen | Hazard Traits - CarcinogenicityDermatotoxicityDevelopmental ToxicityEndocrine ToxicityHepatotoxicity and Digestive System ToxicityImmunotoxicityNeurotoxicityReproductive Toxicity |
| Hazard Classes and Categories | Not Classified |
| Minimum Risk Level | Intermediate Oral: 0.03 ug/kg/day (L134) |
| Treatment | There are no specific treatments for PCB poisoning, since it is not usually recognized until after substantial chronic exposure. Only preventing further exposure and treating the observed symptoms can be done. Acute inhalation can be treated by administering oxygen. (L4) |
| Gesundheitliche Auswirkungen | The most common health effects of PCBs are skin conditions such as chloracne and rashes. Chronic PCB exposure has also been shown to cause liver, stomach and kidney, damage, jaundice, edema, anemia, changes in the immune system, behavioral alterations, and impaired reproduction. (L4) |
| Expositionspfade | Oral (L4)inhalation (L4)dermal |
| Toxizitätsübersicht | The mechanism of action varies with the specific PCB. Dioxin-like PCBs bind to the aryl hydrocarbon receptor, which disrupts cell function by altering the transcription of genes, mainly be inducing the expression of hepatic Phase I and Phase II enzymes, especially of the cytochrome P450 family. Most of the toxic effects of PCBs are believed to be results of Ah receptor binding. Other PBCs are believed to interfere with calcium channels and/or change brain dopamine levels. PCBs can also cause endocrine disurption by altering the production of thyroid hormones and binding to estrogen receptors, which can stimulate the growth of certain cancer cells and produce other estrogenic effects, such as reproductive dysfunction. They will bioaccumulate by binding to receptor proteins such as uteroglobin. (A3, A4, A30, A66) |
Anwendungen & Verwendung
Verwenden
2,2'',3,3'',4'',5,6-Heptachlorobiphenyl is a polychlorinated biphenyl (PCB) congeners.